CERo Therapeutics Holdings, Inc. (CERO) stock
CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.01+0.00 (0.00%)
Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%
CERo Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
CERo Therapeutics's operating cash flow for the twelve months ending Dec 31, 2023 was -$1.52M. For fiscal 2025 it was -$16.10M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.10M | – |
| FY2023 | Dec 31, 2023 | -$1.52M | – |
| FY2022 | Dec 31, 2022 | -$1.09M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.89M | – |
| Q1 FY2026 | Mar 31, 2026 | $2.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$186.61K | – |
| Q3 FY2023 | Sep 30, 2023 | -$256.12K | – |
| Q2 FY2023 | Jun 30, 2023 | -$883.10K | – |
| Q1 FY2023 | Mar 31, 2023 | -$197.78K | – |
| Q4 FY2022 | Dec 31, 2022 | -$373.10K | – |
| Q3 FY2022 | Sep 30, 2022 | -$174.35K | – |
| Q2 FY2022 | Jun 30, 2022 | -$236.71K | – |
| Q1 FY2022 | Mar 31, 2022 | -$308.09K | – |
See a number that looks wrong?